Biomedical Engineering Reference
In-Depth Information
O
OH
O
O
N
N
O
OH
H
O
3
N
O
H
3
N
O
Cl
N
H
N
Pt
O
H
3
N
Cl
NH
2
N
N
NH
2
O
H
2
N
HN
Pt
O
O
Cl
O
O
O
HN
O
Cl
Pt
NH
2
NH
2
O
O
Cl
Pt
9
11
NH
2
OEt
Pt
O
NH
2
NH
2
Cl
NH
3
= EGF
O
Cl
NH
3
NH
O
O
10
12
NH
2
NH
2
O
H
3
N
H
3
N
=
Pt
O
= p hospholipidic- PEG-NH
2
O
Figure 3.6
Structures of compounds
9
-
12
. See also Colour Insert.
Recently, Bhirde
et al.
described the use of compound
11
, a cisplatin-
delivery system based on a drug-SWCNT conjugate, to target cancer cells
in vivo
.
26
The interaction of the epidermal growth factor (EGF) with its
receptor (EGFR), overexpressed on the cell surface of many cancers, has been
exploited to target CNTs both
in vitro
and
in vivo
. The authors demonstrated
the eficient
in vitro
internalisation of the SWCNT-EGF conjugate by proving
that it is actually mediated by the ligand-receptor interaction. Furthermore,
they administered QD-functionalised SWCNTs to tumour-bearing athymic
mice to study short-term biodistribution. The results showed a much higher
accumulation within the tumour mass of the EGF conjugate compared with
the control conjugate without EGF, while small amounts of nanotubes were
found in the spleen, lungs, liver, kidneys and heart, regardless of the presence
of EGF. Finally, the animals were treated with compound
11,
showing a
decrease in tumour growth in comparison with the untargeted SWCNT-
cisplatin conjugate, demonstrating that SWCNTs can effectively deliver
cisplatin
in vivo
, targeted by EGF towards EGFR overexpressing cancer cells.
Search WWH ::
Custom Search